Zolgensma, a life-saving gene therapy drug for spinal muscular atrophy (SMA), is currently one of the most expensive drugs in the world. With a staggering price tag of approximately $2 million per treatment, countless families are unable to afford this crucial medication for their loved ones suffering from SMA. This disease primarily affects children under two years old and without treatment, it can lead to severe disability or even death.

The high cost of Zolgensma puts an unbearable financial burden on families who are already dealing with emotional stress due to their child's illness. Moreover, it restricts access to this vital therapy only to those who can afford it, creating a significant health disparity.

We urge Novartis AG, the manufacturer of Zolgensma, and relevant health authorities worldwide to work together in reducing the cost of this drug. By doing so, they will be ensuring that all patients have equal access to this potentially life-saving treatment regardless of their financial status.

Every signature on this petition brings us one step closer towards making Zolgensma accessible for all SMA patients. Please sign and share our plea for justice and equality in healthcare.